Background: Heart failure is a complex and multifactorial disease that affects millions globally, posing significant challenges to healthcare systems.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

People with type 2 diabetes had significantly fewer heart attacks, strokes, heart failures, and deaths from cardiovascular ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

A team of researchers led by Emory's Chunhui Xu recently found that heart muscle cells can grow and survive in the ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.